Researcher – Early Drug Development, Miltenyi Biotec
Caroline Brandes, M.Sc. Molecular Biomedicine, joined Miltenyi Biotec in 2019 as a researcher in the early-stage drug development group of Dominik Lock. Since then, Caroline Brandes has been developing novel CAR and TCR T cell technologies for cancer immunotherapy, as well as non-viral T cell engineering and manufacturing processes with a focus on electroporation-based and genome-editing techniques.
Got a question for Caroline Brandes?
Get in touch using the contact form linked here and we’ll get back to you shortly